Efficacy of biologic agents for palmoplantar psoriasis: a systematic review and network meta-analysis

伊克泽珠单抗 医学 塞库金单抗 英夫利昔单抗 银屑病 乌斯特基努马 阿达木单抗 依那西普 阿纳基纳 斑块性银屑病 皮肤病科 内科学 银屑病性关节炎 疾病 类风湿性关节炎
作者
Sotirios G. Tsiogkas,Maria G. Grammatikopoulou,Katerina-Maria Kontouli,Ioanna Minopoulou,Dimitrios G. Goulis,Efterpi Zafiriou,Dimitrios P. Bogdanos,Aikaterini Patsatsi
出处
期刊:Expert Review of Clinical Immunology [Informa]
卷期号:19 (12): 1485-1498
标识
DOI:10.1080/1744666x.2023.2272049
摘要

ABSTRACTBackground Palmoplantar psoriasis (PP) represents a localized type of disease. While controversy over its’ classification exists, a hyperkeratotic type, a pustular type and palmoplantar pustulosis (PPP) have been recognized. PP management is regularly supported by biologic agents. Our study aimed to review and synthesize available data regarding the efficacy of approved biologics for PP and PPP.Research design and methods A literature search was conducted in PubMed, CENTRAL, Scopus, and ClinicalTrilas.gov. Utilizing random-effects inverse-variance frequentist network meta-analyses (NMAs), we ranked interventions. The proportion of participants with cleared skin was the primary outcome. Fifty and 75% improvement in palmoplantar psoriasis area severity index (PPASI) were also explored (PPASI50, PPASI75).Results In total, 15 randomized controlled trials (RCTs) exploring the efficacy of on-label adalimumab, bimekizumab, etanercept, guselkumab, infliximab, ixekizumab, secukinumab, and ustekinumab were included. Data for PP were synthesized. Every biologic agent examined, except from infliximab, outperformed placebo. On-label secukinumab exhibited the highest probability of inducing complete resolution. Ixekizumab and infliximab ranked best on inducing PPASI50 and PPASI75. Our review supports that guselkumab is effective for PPP.Conclusions Secukinumab, ixekizumab and infliximab are effective for PP. Research is warranted to produce evidence about the efficacy of biologics in PP and PPP.KEYWORDS: Network meta-analysisanti-IL-17anti-IL-23anti-TNFpalmssoles Declaration of interestsD Bogdanos: lecture honoraria (2020–2022): Menarini Hellas, Boehringer Ingelheim, Genesis Pharma, Fresenius Kabi, congress travel and accommodation support from Hospital Iine, Pfizer, Elpen, Aenorasis Hellas. E Zafiriou: consulting fees: Abbvie, Genesis Pharma, Leo, Novartis, Jannsen, Pharmaserv Lilly, Pfizer, Sanofi, UCB, payment or honoraria: Abbvie, Genesis Pharma, Leo, Novartis, Jannsen, Pharmaserv Lilly, Pfizer, Sanofi, UCB, support for attending meetings: Abbvie, Genesis Pharma, Novartis, Jannsen, Pharmaserv Lilly, Sanofi, UCB. A Patsatsi: consulting fees: Abbvie, Argenx, Genesis Pharma, Leo, Novartis, Jannsen, Pharmaserv Lilly, Pfizer, Sanofi, UCB, payment or honoraria: Abbvie, Argenx, Genesis Pharma, Leo, Novartis, Jannsen, Pharmaserv Lilly, Pfizer, Sanofi, UCB, support for attending meetings: Abbvie, Argenx, Genesis Pharma, Leo, Novartis, Jannsen, Pharmaserv Lilly, Sanofi, UCB. The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.Reviewer disclosuresPeer reviewers on this manuscript have no relevant financial or other relationships to disclose.Author contributionsConceptualization, A Patsatsi and S Tsiogkas; methodology, M Grammatikopoulou, KM Kontouli, S Tsiogkas and I Minopoulou; formal analysis, M Grammatikopoulou, KM Kontouli and S Tsiogkas; investigation, S Tsiogkas, I Minopoulou and M Grammatikopoulou; data curation,, S Tsiogkas, I Minopoulou and M Grammatikopoulou; writing – original draft preparation, S Tsiogkas, M Grammatikopoulou and D Bogdanos; writing – review and editing, S Tsiogkas, M Grammatikopoulou, I Minopoulou, KM Kontouli, D Goulis, D Bogdanos, E Zafiriou, A Patsatsi; visualization, M Grammatikopoulou and S Tsiogkas; supervision, D Bogdanos and A Patsatsi; project administration, D Bogdanos.Data availability statementData sharing does not apply to this study as new data were neither created nor analyzed for this systematic review. Data extraction form is available upon request.AcknowledgmentsWe would like to thank E Rigopoulou for her critical comments.Supplementary materialSupplemental data for this article can be accessed online at https://doi.org/10.1080/1744666X.2023.2272049Additional informationFundingThis paper was not funded.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
2秒前
科研科发布了新的文献求助10
2秒前
大萝贝发布了新的文献求助10
6秒前
8秒前
个性的紫菜应助xtlx采纳,获得10
8秒前
9秒前
香蕉觅云应助小景007采纳,获得10
11秒前
CodeCraft应助害羞的科硕采纳,获得10
11秒前
谢紫玲完成签到,获得积分10
15秒前
17秒前
共享精神应助Cindy采纳,获得10
19秒前
20秒前
20秒前
21秒前
21秒前
ganson发布了新的文献求助10
21秒前
Zheyan发布了新的文献求助10
21秒前
甜甜玫瑰应助Missinmygirl采纳,获得10
22秒前
可爱的函函应助ioei采纳,获得10
24秒前
WANGs完成签到 ,获得积分10
24秒前
传奇3应助liuxuwei采纳,获得10
25秒前
Xu_JY发布了新的文献求助10
25秒前
Agamemnon发布了新的文献求助10
26秒前
26秒前
长孙谷梦完成签到,获得积分10
26秒前
小景007发布了新的文献求助10
27秒前
凯凯完成签到 ,获得积分10
28秒前
28秒前
Agamemnon发布了新的文献求助10
31秒前
Owen应助俭朴的猫咪采纳,获得10
32秒前
32秒前
zhangnan发布了新的社区帖子
32秒前
33秒前
34秒前
35秒前
陈豆豆发布了新的文献求助10
35秒前
含糊的小松鼠完成签到 ,获得积分10
36秒前
情怀应助Xu_JY采纳,获得10
37秒前
37秒前
leyna发布了新的文献求助10
37秒前
高分求助中
One Man Talking: Selected Essays of Shao Xunmei, 1929–1939 1000
Yuwu Song, Biographical Dictionary of the People's Republic of China 700
[Lambert-Eaton syndrome without calcium channel autoantibodies] 520
Sphäroguß als Werkstoff für Behälter zur Beförderung, Zwischen- und Endlagerung radioaktiver Stoffe - Untersuchung zu alternativen Eignungsnachweisen: Zusammenfassender Abschlußbericht 500
少脉山油柑叶的化学成分研究 430
Revolutions 400
MUL.APIN: An Astronomical Compendium in Cuneiform 300
热门求助领域 (近24小时)
化学 材料科学 医学 生物 有机化学 工程类 生物化学 纳米技术 物理 内科学 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 电极 光电子学 量子力学
热门帖子
关注 科研通微信公众号,转发送积分 2454372
求助须知:如何正确求助?哪些是违规求助? 2126151
关于积分的说明 5414858
捐赠科研通 1854798
什么是DOI,文献DOI怎么找? 922503
版权声明 562340
科研通“疑难数据库(出版商)”最低求助积分说明 493566